Pfizer Inc's Hold recommendation, which was recently downgraded from a Buy to Hold, is the conclusion of an analytical process that is proprietary and produced outcomes that were above average in 4 areas: an economic sector ranked above average in attractiveness, an industry group ranked above average in attractiveness, a ranking in the company's sector that is in the top half, and analytical scores that are near average; and produced below average conclusions in 2 areas: ranking in its industry group that is in the middle third-below average and a quantitative risk/reward calculation that is average.

Portfolio Grader currently ranks PFE as a Buy. The approach to fundamental and quantitative metrics used in this analytical tool evaluates and ranks nearly 5,000 stocks each week. The shares have been upgraded from a Hold to a Buy in the last week.

The Buy recommendation, which was recently up graded from a Hold to Buy, for Pfizer Inc is the outcome of an analytical process that is proprietary which yielded conclusions that were above average in 5 area: an economic sector ranked above average in attractiveness, an industry group ranked above average in attractiveness, a ranking in the company's sector that is in the top third, ranking in its industry group that is in the top half, and a quantitative risk/reward calculation that is better than average; and produced below average results in 1 areas: analytical scoring that is near average.

Pfizer Inc (NYSE:PFE) is one of 38 companies within the Pharmaceuticals: Major GICS industry group, which is in turn part of the 657 company GICS Health Technology sector. PFE's market value is $220.2 billion which falls in the top decile in its industry group. The ranking for PFE by Portfolio Grader places it 20 among the 38 companies in this industry group, giving it a lower than average position; in the top half of the sector with a ranking of 270 among the 657 companies in the sector, and number 1,894 in the nearly 5,000 company Portfolio Grader universe.

Pfizer Inc (NYSE:PFE) is a constituent of the 38 company Pharmaceuticals: Major GICS industry group, which is a segment of the 657 company GICS Health Technology sector. PFE's market value is $220.2 billion which falls in the top decile in its industry group. The ranking for PFE by Portfolio Grader places it 20 among the 38 companies in this industry group, giving it a lower than average position; in the top half of the sector with a ranking of 270 among the 657 companies in the sector, and number 1,894 in the nearly 5,000 company Portfolio Grader universe.

The current recommendation of Hold for Pfizer Inc (NYSE:PFE) has been derived by using Louis Navellier's methodology for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for the last month.

Portfolio Grader currently ranks Pfizer Inc (NYSE:PFE) a Hold. The methodology for investing incorporated in this analytical tool developed by Louis Navellier assesses and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. PFE has maintained this ranking for the last month.